Craft

Relay Therapeutics

Total Funding

$520 M

Revenue

$1.4 M

FY, 2022

Relay Therapeutics Summary

Company Summary

Overview
Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016 with $57 million in Series A venture capital financing from Third Rock Ventures and an affiliate of D.E. Shaw Research. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!
Type
Private
Status
Active
Founded
2016
HQ
Cambridge, MA, US | view all locations
Website
http://relaytx.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Brian Adams

    Brian Adams, General Counsel

    • Tom Catinazzo

      Tom Catinazzo, Vice President, Finance

      • Don Bergstrom

        Don Bergstrom, Executive Vice President, Head of Research and Development

        • Dorothee Kern

          Dorothee Kern, Founder

          LocationsView all

          1 location detected

          • Cambridge, MA HQ

            United States

            399 Binney St 2nd Floor

          Relay Therapeutics Financials

          Summary Financials

          Revenue (Q3, 2023)
          $25.2M
          Net income (Q3, 2023)
          ($65.7M)
          Cash (Q3, 2023)
          $151.3M
          EBIT (Q3, 2023)
          ($73.6M)

          Footer menu